Overview
Latest Data in FSGS and IgAN
Pathways to Improved Care in FSGS and IgAN
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Expert faculty, Dr. Richard Lafayette, explores clinical trial data coming out of a recent nephrology meeting, and provides learners with up-to-date knowledge on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). This brief interview-style video offers insights into the patient burden of chronic kidney disease, advances in understanding the pathophysiology, and emerging approaches to treatment for this patient population. Dr. Lafayette discusses current barriers, emerging evidence, and strategies to incorporate advances.
This activity is intended for nephrologists, primary care, internal medicine, and other clinicians interested in treating patients with focal segmental glomerulosclerosis and/or IgA nephropathy.
Focal segmental glomerulosclerosis and IgAN are glomerular disorders that contribute to kidney failure and the need for dialysis and/or transplant. Although both are associated with kidney injury, they have different pathophysiologies, along with considerable disease heterogeneity. There are no currently approved therapies and the management of FSGS and IgAN is challenging. Recent research has identified potential therapeutic targets for individuals with these progressive kidney diseases and there are a number of ongoing clinical trials. This education brings clinicians up-to-date on potential treatment targets and agents in the pipeline for progressive kidney disease.
Upon completion of this activity, participants will be able to:
• Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
• Outline emerging therapies and pathways for FSGS and IgAN
• Interpret clinical trial data and endpoints from clinical trials with emerging therapies
• Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
• Outline emerging therapies and pathways for FSGS and IgAN
• Interpret clinical trial data and endpoints from clinical trials with emerging therapies
Supported by an educational grant from Travere Therapeutics, Inc.
Richard Lafayette, MD
Stanford Department of Medicine, Nephrology
Stanford, CA
Stanford Department of Medicine, Nephrology
Stanford, CA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Richard Lafayette, MD (Faculty)
Advisor or Review Panel member: Calliditas Therapeutics, Chinook Therapeutics, Novartis, Otsuka/Visterra, Travere Therapeutics, Vera Therapeutics
Consultant (Occasional): Novartis, Omeros
Grant/Research Support recipient: Calliditas Therapeutics, Chinook Therapeutics, Omeros, Otsuka/Visterra, Travere Therapeutics, Vera Therapeutics
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
